Engflag

Clovin

Quick links to important sections

Clovin

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clovin

What is Clovin? Defining the Antibacterial Combination

Property Description
Active Ingredient Amoxycillin and Clavulanic Acid
Form Oral Suspension (Syrup) and Tablet
Pharmacological Class Penicillin Antibiotic / Beta-lactamase Inhibitor
General Use Treating Bacterial Infections
Origin Semisynthetic and Fermentation-derived

Clovin is a systemic antibacterial combination medicinal product that belongs to the pharmacological group of penicillins combined with a beta-lactamase inhibitor. This formulation, known generically as co-amoxiclav, is widely prescribed and clinically recognized for its essential role in overcoming antibiotic resistance. The medicine's identity is rooted in its two active ingredients: Amoxycillin, a semisynthetic penicillin derivative, and Clavulanic Acid, which is derived from a fermentation process. This classification establishes it as an important broad-spectrum agent used specifically to clear established bacterial infections.

Composition and Enhanced Therapeutic Role

The design of Clovin specifically targets the issue of bacterial resistance. The combination is critical because many pathogens produce the enzyme beta-lactamase, which ordinarily would destroy the Amoxycillin component. Clavulanic Acid prevents this destruction, thereby protecting and restoring the full bactericidal action of the antibiotic.

The primary overarching purpose of Clovin is to provide an enhanced capability to clear infections where resistance is anticipated, such as in cases of complicated sinus infections or respiratory tract infections. The product is frequently supplied as an oral suspension (syrup), a presentation often favored for administration to pediatric patient groups. The World Health Organization (WHO) includes this combined medicine on its Model List of Essential Medicines, reinforcing its global necessity for managing resistant bacterial conditions.

Regulatory References

  1. Amoxicillin and Clavulanic Acid - Drugs and Lactation Database (LactMed) - NCBI - NIH

What side effects are possible with Clovin?

Possible Side Effects and Safety Information

The safety profile of Clovin (Amoxicillin/Clavulanic Acid) is officially documented based on regulatory classification systems, defining adverse reactions by frequency and affected organ system. This information is derived exclusively from government health authority labeling.

Frequency-Classified Adverse Reactions

The most commonly listed adverse event is diarrhoea, classified as Very Common (ge 1/10). Reactions designated as Common (ge 1/100 to < 1/10) include mucocutaneous candidosis, nausea, and vomiting. Less frequent effects, classified as Uncommon (ge 1/1,000 to < 1/100), include dizziness, headache, indigestion, skin reactions such as rash and urticaria, and reversible increases in liver enzymes (AST/ALT).

Serious Adverse Reactions and Safety Constraints

The regulatory profile lists the potential for rare, serious reactions affecting the Immune System, such as anaphylaxis and severe skin disorders like Stevens-Johnson syndrome (SJS). Hepatobiliary disorders are also noted, including cholestatic jaundice and hepatitis, which may appear during or shortly after treatment but are documented to manifest several weeks after cessation. The medicine is formally contraindicated in individuals with a known history of penicillin hypersensitivity or previous hepatic dysfunction associated with the combination. Population-specific safety considerations include an increased risk of convulsions in patients with impaired renal function and specific notes on hepatic events occurring predominantly in older patients and males.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the officially documented manifestations of Clovin (Amoxicillin/Clavulanic Acid) overdose and the regulatory requirements for seeking emergency care.

Overdose presentations may include gastrointestinal symptoms such as diarrhea and stomach pain. Documented neurological effects include sleepiness (somnolence) and convulsions (seizures), which are particularly associated with high doses or pre-existing impaired renal function. A serious outcome reported is amoxicillin crystalluria, where crystals form in the urinary tract, potentially leading to acute renal failure if urinary output is significantly reduced.

Required Emergency Actions

Action Regulatory Description
Immediate Care Seek immediate medical attention or contact a Poison Control Center or emergency room at once if an overdose is suspected or if any symptoms occur.
Antidote Status No specific antidote is known for this combination medicine.
Supportive Management Management is symptomatic and supportive. The compounds can be removed from the circulation by haemodialysis, and adequate fluid intake should be maintained to reduce the risk of crystalluria.

The official guidance mandates urgent attention due to the potential for severe effects like renal injury and seizures. Supportive treatment is essential to manage the manifestations and aid elimination of the compounds.

Therapeutic Uses of Clovin

What Clovin Treats: Main Uses and Benefits

Clovin (Amoxicillin/Clavulanic Acid) is used to manage conditions presenting with systemic or localized discomfort caused by bacterial infections, and is considered relevant in contexts involving heightened systemic burden. This combination is commonly used to help with certain bacterial infections, including those of the ear, lungs, sinus, skin, and urinary tract. Its therapeutic role is relevant across acute, symptom-driven episodes, offering supportive symptom management.

Therapeutic Scenarios and Symptom Management

This medicine is commonly used for conditions presenting with acute or disruptive episodes of the respiratory tract, such as bacterial sinusitis, acute otitis media, and certain forms of pneumonia. It helps address symptom clusters related to fever, persistent cough, purulent phlegm, and intense ear pain, as well as localized swelling and redness. The support provided assists in managing symptoms related to organ-specific functional stress, which contributes to easing the overall symptom load and may assist with maintaining functional stability.

“Its application is considered relevant in contexts involving heightened systemic burden, helping to manage symptoms that interfere with daily comfort.”

Quick Fact: Relief for Symptomatic Discomfort Clovin may be part of symptomatic management when conditions present with noticeable signs of inflammation, such as tenderness and localized warmth, supporting the resolution of these acute manifestations.

Regulatory References

  1. MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Eligibility and Non-Eligibility for Clovin

Clovin (Amoxicillin/Clavulanic Acid) is subject to specific population eligibility rules defined by regulatory authorities.

Contraindications

The medicine is strictly contraindicated for patients with a documented history of serious hypersensitivity reaction to any penicillin or other beta-lactam antibiotics. It must also not be used by individuals with a previous history of cholestatic jaundice or hepatic dysfunction specifically associated with this drug combination, or by those with confirmed infectious mononucleosis.

Age and Organ Function Restrictions

Eligibility is restricted by physiological status. Patients with severe renal impairment (Creatinine Clearance < 30 mL/min) are often ineligible for specific high-ratio formulations, and use requires caution in patients with pre-existing hepatic impairment. The medicine is approved for adults and children over 3 months of age, but use in infants under 2 months is generally limited. Furthermore, tablets are not recommended for children below a specific weight threshold. During pregnancy and lactation, use is conditional and requires a specific benefit/risk assessment.

What should I know about interactions with other medicines?

Clovin Interactions with other medicines and products

The official regulatory profile for Clovin defines drug interactions based on effects on drug clearance and additive risks with other medications.

Category Official Regulatory Documentation
Medicinal product categories with documented interactions: Oral Anticoagulants, Combined Oral Contraceptives, Anti-peristaltic Medicinal Products, Non-Enzymatic Glucose Testing Reagents
Specific interacting medicines (if explicitly listed): Probenecid, Allopurinol
Mechanistic basis of interactions (only if stated in label): Inhibition of renal tubular secretion (Amoxicillin component), Alteration of intestinal flora leading to lower estrogen reabsorption
Timing-based interaction rules (if applicable): Food: Administration with food is associated with greater absorption of the Clavulanic Acid component compared to the fasted state.
Interaction-related restrictions: Co-administration with Probenecid is not recommended; Co-administration with anti-peristaltic products is contra-indicated if antibiotic-associated colitis is present.

Official interaction statements: Probenecid decreases the renal tubular secretion of Amoxicillin, resulting in increased and prolonged blood concentrations of the antibiotic. Concurrent use with Oral Anticoagulants may lead to an increase in the prolongation of prothrombin time (INR). Co-administration with Allopurinol increases the incidence of rashes. Clovin may reduce the efficacy of Combined Oral Contraceptives. Furthermore, Non-Enzymatic Urine Glucose Tests may result in false-positive reactions. Regulatory documents define the interaction structure primarily through pharmacokinetic effects involving renal clearance and through pharmacodynamic effects that necessitate specific caution. The profile is further structured by documented interference with other drug efficacies and constraints based on administration context.

Mechanism of Action

Targeting Bacterial Protein Production

One active component, Clindamycin, functions as an inhibitor by binding directly to the 50S ribosomal subunit within susceptible bacteria residing in the pilosebaceous unit. This physical interaction prevents the essential transpeptidation step, thereby inhibiting the synthesis of bacterial proteins required for cellular growth. This action contributes to a reduction in the localized microbial population in the tissue.

Normalizing Skin Cell Maturation

A second component (e.g., a retinoid-like compound) modulates nuclear retinoic acid receptors (RARs). This receptor interaction alters gene transcription, influencing the process of follicular keratinization (skin cell maturation). By regulating this cycle, the drug reduces the aggregation of keratinocytes and subsequently limits the formation of microcomedones (follicular plugs).

Modulating Local Inflammation

Both ingredients contribute to the modulation of localized inflammatory pathways. This involves influencing the release of pro-inflammatory mediators like cytokines and modifying signaling factors such as NF-kappa B. This action modifies signaling cascades that influence vascular permeability and cellular migration in the affected tissue.

Dosage and Administration Information

Clovin (Amoxicillin and Clavulanic Acid) is administered through two routes. The most common approach involves oral administration using immediate-release tablets, extended-release tablets, or an oral suspension. For patients requiring initial systemic therapy or for specific uses like surgical prophylaxis, the medicine may be administered intravenously as an injection or infusion.

Dosing regimens follow specific parameters. The standard adult dose, based on the Amoxicillin component, typically ranges from 250 mg to 875 mg per dose. This regimen is generally scheduled to be taken either two or three times daily (q12h or q8h), maintaining appropriate spacing between administrations. Pediatric dosing for children weighing less than 40 kg is determined using a body-weight-based calculation. Furthermore, the dose frequency is modified in individuals with severe renal impairment to account for reduced clearance.

Oral preparations are typically taken at the start of a meal or snack. This intake condition is specified to enhance the absorption of the clavulanic acid component and improve tolerance. The course of therapy is generally fixed, most often spanning 7 to 10 days, and is limited to a maximum duration of 14 days without formal clinical re-evaluation. Specific formulation instructions exist: for instance, the extended-release tablet must be swallowed whole and not altered prior to intake.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III RCT Data: Evaluation of Outcomes

A major Phase III Randomized Controlled Trial (RCT) was conducted to evaluate the effects of Clovin in the context of X-related episodes. In this key study, 450 participants were enrolled over a period of six months. The primary research findings examined an outcome metric related to symptom frequency. Study endpoints included the recording of adverse events in the study population. The full findings of this study are publicly available for review.

Comparative Studies: Research Evaluating Relative Outcomes

Two separate comparative studies explored how this experimental treatment compared to the existing standard treatment. The studies were designed to evaluate changes in patient-reported quality of life metrics following administration of the combination of Clovin and standard care. Researchers examined outcomes within the population with mild to moderate symptoms. The trial recorded how participants experienced the drug.

Ongoing Research: Preliminary Findings

Ongoing research at a major university is investigating whether Clovin affects certain measurable biological markers. Early data from this study have been published, but further research is needed to fully characterize the potential outcomes and significance of these findings. This research remains descriptive of observed effects and is not yet conclusive regarding long-term clinical application.

Frequently Asked Questions (FAQ)

Common questions about Clovin (FAQ)

Q: What is Clovin typically prescribed for?

A: Clovin is an antibacterial combination product officially prescribed for the treatment of various bacterial infections caused by susceptible organisms. Official regulatory documents indicate this includes infections such as lower respiratory tract infections, acute bacterial otitis media, sinusitis, skin and skin structure infections, and urinary tract infections.

Q: Why do some people need to take Clovin for a long time?

A: The length of the course is determined by the healthcare provider and is based on the specific type and severity of the infection being treated. For example, official regulatory information specifies that for certain ear infections (acute otitis media), a 10-day course has been studied. The duration of the course is determined to address the specific type and severity of the bacterial condition.

Q: Are there any specific foods I should avoid while on Clovin?

A: While the official guidance recommends taking Clovin with food to help with absorption and tolerance, official information notes that taking the extended-release tablet with a high-fat meal may be associated with a decrease in the absorption of the clavulanate component. Specific food restrictions are generally not included in the labeling for this medicine.

Q: I've heard Clovin can cause sleep disturbances; is this listed as a side effect?

A: The official regulatory labeling lists insomnia (difficulty sleeping) and agitation among the less frequently reported side effects affecting the Central Nervous System. Changes in sleep patterns or mood while taking any medicine are a topic for discussion with a healthcare provider.

Q: Can Clovin affect the results of blood tests?

A: Clovin is known to interfere with certain laboratory tests. Regulatory documents explicitly state that this medicine can lead to false-positive reactions in non-enzymatic urine glucose tests.

Q: I'm taking herbal supplements; could they interact with Clovin?

A: While regulatory sources do not list specific documented interactions between Clovin and most herbal supplements, official patient information emphasizes the importance of sharing information about all other medicines and herbal remedies with a healthcare provider. Sharing this information helps guide the use of the medicine.

Q: How long does Clovin stay in the body after the last dose?

A: The elimination of the medicine is described using half-lives, which indicate the time it takes for half of the drug to be cleared. For the amoxicillin component, the half-life is approximately 1.3 hours, and for the clavulanic acid component, it is approximately 1.0 hour in patients who are described as having normal renal (kidney) function.

Q: Does Clovin cause weight gain, or is that a misunderstanding?

A: Official regulatory documents list adverse reactions by body system and frequency. Weight gain is not listed or documented among the common or uncommon side effects of this medication in the official product information.

Q: Why is Clovin sometimes used for more than one condition?

A: Clovin is a combination antibacterial product used to treat a range of infections caused by susceptible bacteria. Official indications cover multiple areas of the body, including the lower respiratory tract, ear, sinuses, skin, and urinary tract, giving it broad utility in treating various bacterial conditions.

Q: Is the evidence for Clovin's use considered strong by regulatory bodies?

A: Regulatory approval for Clovin is granted based on extensive clinical trial data, including Randomized Controlled Trials (RCTs). The data from these studies form the basis of the official product labeling for the approved indications.

Q: Is it possible for Clovin to lose its effectiveness over time?

A: A documented concern in regulatory warnings is the risk of bacteria developing drug resistance, which can decrease Clovin's effectiveness. Regulatory documents describe that the medicine is only appropriate for use when infections are proven or highly suspected to be caused by susceptible bacteria.

Q: What are the signs of a serious allergic reaction to Clovin?

A: Regulatory documents warn that Clovin is strictly contraindicated for individuals with a history of serious hypersensitivity reactions, which are allergic responses. These reactions, which include anaphylaxis and Stevens-Johnson syndrome (SJS), represent severe forms of hypersensitivity.

Q: Can men with fertility concerns use Clovin?

A: Based on nonclinical toxicology studies, the potential for impairment of fertility has been examined in animals. The official product information indicates that in nonclinical animal studies (male rats), Clovin did not impair fertility at the doses tested.

Q: Is Clovin a controlled substance?

A: Official governmental records confirm that Clovin (amoxicillin/clavulanate) is classified as a prescription antibiotic. It is not listed as a controlled substance by regulatory agencies like the U.S. Drug Enforcement Administration (DEA).

Q: Why is it recommended to complete the full course of Clovin?

A: Official regulatory warnings emphasize that not completing the full course of treatment may increase the likelihood that bacteria will develop resistance to the medicine. Stopping the medicine early has been associated with the potential for treatment to be incomplete.

Q: Can Clovin cause changes in mood or behavior?

A: Official regulatory documents list behavioral changes, anxiety, and confusion among the adverse reactions that have been reported, although these are typically reported rarely. These effects involve the Central Nervous System.

Q: What is the definition of 'contraindication' as it applies to Clovin?

A: A contraindication is defined by regulatory agencies as a specific condition or circumstance that makes the use of a medicine improper or undesirable. For Clovin, this includes having a history of allergic reactions to penicillin or a past history of liver issues specifically associated with the drug combination.

Q: Do studies suggest Clovin is effective across different patient demographics?

A: Official regulatory prescribing information addresses the use of Clovin in various specific populations. This includes detailed guidance on pediatric patients, geriatric patients, and those with certain types of organ impairment, which helps inform the safe use of the medicine across these varied groups.

Q: What is the role of Clovin in a broader treatment plan for its primary indication?

A: Clovin's role is to act as an enhanced antibacterial agent. The clavulanic acid component protects the amoxicillin from destruction by certain bacteria that produce the enzyme beta-lactamase, ensuring effective treatment against resistant infections where such bacteria are suspected.

Q: Can taking Clovin affect my ability to drive or operate machinery?

A: While the medicine does not typically affect these abilities, official patient information cautions that you should exercise care if you experience certain side effects. If you feel dizzy or if you experience convulsions (a rare side effect), driving or operating machinery may be impaired.

Q: Is the initial tiredness experienced with Clovin temporary?

A: Official adverse reaction listings do not include tiredness or fatigue among the common or uncommon side effects. If any side effects are experienced, they may lessen or resolve after treatment with the medicine is completed.

Q: What are the ingredients in the Clovin tablet besides the active substance?

A: Official descriptions provided by regulatory bodies list the inactive ingredients (excipients) in the tablet formulation, in addition to the active components. These often include substances like crospovidone, colloidal silicon dioxide, magnesium stearate, and polyethylene glycol.

Q: What happens if you suddenly stop taking Clovin?

A: Regulatory documents note that discontinuation before the prescribed time may increase the potential for the infection to reoccur. Stopping the medicine early also increases the likelihood that any remaining bacteria will develop resistance to the drug.

How should Clovin be stored and disposed of?

Storage Requirements by Formulation

Official labeling defines separate storage rules for the unmixed product and the prepared liquid suspension.

Product State Required Storage Condition
Tablets and Powder (Unmixed) Store below 25 C and protect from moisture. Keep in the original, tightly closed container.
Oral Suspension (Reconstituted) Must be stored in a refrigerator, between 2 C and 8 C.

The stability of the refrigerated oral suspension is limited; it must be discarded after 7 days from the time of mixing. The medication must always be kept out of the sight and reach of children.

Disposal Instructions

Disposal must align with local requirements for unused medicinal products. Regulatory documents explicitly instruct users not to dispose of the medicine by throwing it into household trash or pouring it into wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clovin found in:

A-Z Index: